Gynecologic cancers: factors affecting survival after pulmonary metastasectomy.
BACKGROUND
Little information is available regarding long-term survival after pulmonary metastasectomy for gynecologic malignancies.


METHODS
All patients who underwent pulmonary resection for gynecologic malignancies at our institution between January 1985 and June 2001 were reviewed. Factors affecting long-term survival were analyzed.


RESULTS
There were 103 patients, 70 of whom had metastatic disease limited to the lungs. Median age of these 70 patients was 59.4 years (range, 31 to 80 years). The primary tumor originated in the uterine corpus in 37 patients, endometrium in 23, cervix in 7, ovaries in 2, and vagina in 1. Histopathology was leiomyosarcoma in 29 patients, adenocarcinoma in 23, other sarcoma in 11, squamous cell carcinoma in 5, and choriocarcinoma and endolymphatic stromal myosis in 1 each. The median time interval between the first gynecologic procedure and pulmonary resection was 24 months (range, 0 to 237 months). A wedge excision was performed in 44 patients, lobectomy in 14, bilobectomy in 2, pneumonectomy in 1, and a combination in 9. Five patients (7%) had an incomplete resection. Eighteen patients (25.7%) developed at least one complication and 1 died (operative mortality, 1.4%). At last follow-up, 35 had died, and the median follow-up among those who were still alive was 36 months (range, 6 months to 13 years). Five-year and 10-year survival was 46.8% (95% confidence interval, 34.2% to 63.0%) and 34.3% (95% confidence interval, 19.7% to 52.5%), respectively. Factors that adversely affected survival include a disease-free interval between the first gynecologic procedure and pulmonary resection of less than 24 months (p = 0.004) and a primary site located in the cervix (p < 0.001).


CONCLUSIONS
Pulmonary resection for metastatic gynecologic cancer in selected patients is safe and effective. Both a short disease-free interval between the primary gynecologic procedure and pulmonary metastasectomy, and a primary cervical tumor had an adverse effect on survival.
Clavero
Jose M
JM
Division of General Thoracic Surgery, Rochester, Minnesota, USA.
Deschamps
Claude
C
Cassivi
Stephen D
SD
Allen
Mark S
MS
Nichols
Francis C
FC
Barrette
Brigitte A
BA
Larson
Dirk R
DR
Pairolero
Peter C
PC
D000230:Adenocarcinoma / Q000401:mortality / Q000556:secondary / Q000601:surgery / Q000628:therapy; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000556:secondary / Q000601:surgery / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D002822:Choriocarcinoma / Q000401:mortality / Q000556:secondary / Q000601:surgery / Q000628:therapy; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D036821:Endometrial Stromal Tumors / Q000401:mortality / Q000556:secondary / Q000601:surgery / Q000628:therapy; D005260:Female; D005500:Follow-Up Studies; D005833:Genital Neoplasms, Female / Q000401:mortality* / Q000628:therapy; D006801:Humans; D007044:Hysterectomy; D007890:Leiomyosarcoma / Q000401:mortality / Q000556:secondary / Q000601:surgery / Q000628:therapy; D015993:Life Tables; D008175:Lung Neoplasms / Q000401:mortality / Q000556:secondary* / Q000601:surgery; D008197:Lymph Node Excision; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000401:mortality / Q000628:therapy; D010052:Ovariectomy; D011013:Pneumonectomy / Q000379:methods / Q000706:statistics & numerical data*; D011183:Postoperative Complications / Q000401:mortality; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D012307:Risk Factors; D012509:Sarcoma / Q000401:mortality / Q000556:secondary / Q000601:surgery / Q000628:therapy; D016019:Survival Analysis; D002583:Uterine Cervical Neoplasms / Q000401:mortality / Q000628:therapy; D014594:Uterine Neoplasms / Q000401:mortality / Q000628:therapy; D014625:Vaginal Neoplasms / Q000401:mortality / Q000628:therapy